Verastem VSTM
NASDAQ VSTM
$9.09 +0.36 (+4.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Verastem (VSTM) Current Deferred Revenue (2022 - 2023)

Updated

Verastem (VSTM) recorded Current Deferred Revenue of $327,000 in Q4 2023.

Analysis

Verastem (VSTM) Current Deferred Revenue (2022 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Verastem 824.71 Mn 172.86 Mn 20.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 327,000.00
Sep 30, 2023 1.04 Mn
Jun 30, 2023 744,000.00
Mar 31, 2023 1.40 Mn
Dec 31, 2022 710,000.00
Sep 30, 2022 965,000.00
API Access

Verastem Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=VSTM&period=max&api_key=YOUR_API_KEY